Top

Annals of Hematology

Published in:

01-02-2019 | Letter to the Editor

Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review

Authors: Eunjung Park, Mihn-Sook Jue

Published in: Annals of Hematology | Issue 2/2019

Excerpt

Dear Editor, …

Hutchinson J (1868) Outbreak of a large crop of moles. Remarks as to possible connection with melanosis. J Cutan Med Dis Skin 1:170–171

Amitay-Laish I, Stemmer SM, Lacouture ME (2011) Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 24(4):386–395. https://doi.org/10.1111/j.1529-8019.2011.01431.x CrossRefPubMed

Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V (2004) Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 15(2):358–359CrossRefPubMed

Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, Stoof TJ, van de Kerkhof PC (2006) Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 154(5):880–884. https://doi.org/10.1111/j.1365-2133.2006.07189.x CrossRefPubMed

Kim M, Yoon YH, Lee JH, Kim DW, Park HJ (2017) Eruptive melanocytic naevi caused by radotinib therapy in patients with chronic myeloid leukaemia: 10 cases and a literature review. Acta Derm Venereol 97(1):115–116. https://doi.org/10.2340/00015555-2475 CrossRefPubMed

Perry BM, Nguyen A, Desmond BL, Blattner CM, Thomas RS, Young RJ (2016) Eruptive nevi associated with medications (ENAMs). J Am Acad Dermatol 75(5):1045–1052. https://doi.org/10.1016/j.jaad.2016.04.064 CrossRefPubMed

Won KH, Jo SY, Lee YJ, Chang SE (2016) Radotinib-induced lentiginosis: a report of an adverse cutaneous reaction associated with a tyrosine kinase inhibitor. Clin Exp Dermatol 41(2):162–165. https://doi.org/10.1111/ced.12706 CrossRefPubMed

Woo YR, Kim JS, Kim DW, Park HJ (2017) Development of dysplastic nevus during radotinib therapy in patients with chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 83(6):704–707. https://doi.org/10.4103/ijdvl.IJDVL_1030_16 CrossRefPubMed

Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW (2017) Phase III clinical trial (RERISE study) results of efficacy and safety of Radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res 23(23):7180–7188. https://doi.org/10.1158/1078-0432.Ccr-17-0957 CrossRefPubMed

10.

Eskazan AE, Keskin D (2017) Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol 8(9):237–243. https://doi.org/10.1177/2040620717719851 CrossRefPubMedPubMedCentral

Title: Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review
Authors: Eunjung Park
Mihn-Sook Jue
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3444-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2019

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy

Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia

Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration

Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma

Treating early-stage myelofibrosis

Validation of the Marginal Zone Lymphoma International Prognostic Index

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage